A phase II trial of apalutamide for intermediate‐risk prostate cancer and molecular correlates
Andrew W. Hahn(The University of Texas MD Anderson Cancer Center), John W. Davis(The University of Texas MD Anderson Cancer Center), John Papadopoulos(The University of Texas MD Anderson Cancer Center), Justin R. Gregg(The University of Texas MD Anderson Cancer Center), Anh Hoang(The University of Texas MD Anderson Cancer Center), Patrick G. Pilié(The University of Texas MD Anderson Cancer Center), Patricia Troncoso(The University of Texas MD Anderson Cancer Center), Louis L. Pisters(The University of Texas MD Anderson Cancer Center), John F. Ward(The University of Texas MD Anderson Cancer Center), Chad D. Huff(University of Utah), Curtis A. Pettaway(The University of Texas MD Anderson Cancer Center), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Brian F. Chapin(The University of Texas MD Anderson Cancer Center), Yao Yu(The University of Texas MD Anderson Cancer Center), Xuemei Wang(The University of Texas MD Anderson Cancer Center), Miao Zhang(Qingdao University), Marisa Lozano(The University of Texas MD Anderson Cancer Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Lisly Chéry(The University of Texas MD Anderson Cancer Center), Bradley M. Broom(The University of Texas MD Anderson Cancer Center)
Cited by 4
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k